gip/glp-1 receptor agonist mechanism of action Tirzepatide's Unique Current Insights, Advantages and Challenges

Doctor-developed bundle cultivating targeted restoration across the Gut-Metabolic Axis: GLP-1 boosting + Weight Support + Digestive Support + Heart and Circulatory Support + Caffeine-Free Energy

In clinical trials, people using GLP-1 drugs lost an average of about 10 pounds more than people using a placebo

Highlights from the American Diabetes Association on type 2 diabetes care

ORLANDO, Fla

The approval could expand access to an effective therapy for managing obesity.

Eli Lilly have a new, once-monthly GLP1/GIP agonist (Brenipatide) and they're running some fascinating trials with it Smoking cessation, bipolar disorder, schizophrenia, opioid use disorder, depression, alcohol use disorder, and asthma